Apellis Pharmaceuticals Inc APLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm
-
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
-
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
-
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $28.06
- Day Range
- $27.33–28.37
- 52-Week Range
- $26.69–73.80
- Bid/Ask
- $27.35 / $27.54
- Market Cap
- $3.35 Bil
- Volume/Avg
- 1.5 Mil / 1.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.34
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 702
- Website
- https://www.apellis.com
Comparables
Valuation
|
Metric
|
APLS
|
ACLX
|
YMAB
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 12.66 | 8.61 | 6.62 |
Price/Sales | 5.34 | 27.51 | 7.16 |
Price/Cash Flow | — | 507.02 | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
APLS
|
ACLX
|
YMAB
|
|---|---|---|---|
Quick Ratio | 3.95 | 5.85 | 2.67 |
Current Ratio | 5.08 | 6.01 | 2.92 |
Interest Coverage | −10.38 | −28.35 | — |
Quick Ratio
APLS
ACLX
YMAB
Profitability
|
Metric
|
APLS
|
ACLX
|
YMAB
|
|---|---|---|---|
Return on Assets (Normalized) | −28.86% | −1.88% | −10.89% |
Return on Equity (Normalized) | −94.31% | −3.31% | −14.29% |
Return on Invested Capital (Normalized) | −53.87% | −7.10% | −16.96% |
Return on Assets
APLS
ACLX
YMAB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xxwyfgfb | Hyjbc | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Bgfmysg | Rgdphlt | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lltmcdpg | Vsvzx | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xjvfsnd | Tttcfzk | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Vgdqpxqn | Gpc | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Mqhgtkf | Plcc | $29.2 Bil | |||
| Moderna Inc
MRNA
| Bzhbkygs | Dtywb | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Ydjpdtft | Sykl | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hddrkjnnc | Ynlyzy | $13.2 Bil | |||
| Incyte Corp
INCY
| Fnjxjbcy | Cxdbbll | $13.0 Bil |
United States